Prognostic biomarkers provide information about the likely course of the cancer irrespective of treatment. For example, the presence of HER2 overexpression in breast cancer is associated with a more aggressive disease and poorer prognosis. Identifying such biomarkers can help in stratifying patients based on their risk and tailoring the treatment accordingly.
